Pasithea Therapeutics (KTTA) announced that the external Safety Review Committee, SRC, recommended proceeding to cohort 4, 15mg capsule, without modifications. This recommendation was based on the absence of any dose limiting toxicities, DLTs. In addition, no rash was observed in any of the first 9 patients who received PAS-004. The Company has decided to add a cohort 4b to the trial, which will consist of 3 additional patients and introduce an alternate formulation which is intended for commercial use.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KTTA:
- Pasithea Therapeutics files to sell 3.74M shares of common stock for holders
- Pasithea Therapeutics prices $5M at-the-market private placement at $4.10/share
- Morning Movers: Micron and Accenture rise following quarterly results
- Pasithea Therapeutics announces initial data from Phase 1 trial of PAS-004
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue